Patients vary in their responses to drug therapy, and some of that variability is genetically determined. Vascular pharmacogenomics is the research approach aimed at identification of genomic markers that are associated with variability in drug response, drug-related outcomes, or drug-related adverse events. Examples from vascular specific therapeutic areas include cholesterol management, arrhythmias, stroke, heart failure, hypertension, warfarin anticoagulation, and anti-platelet agents.
The approaches to identifying genetic contributors to variable cardiovascular and neurovascular drug actions include:
1. Identification a series of genes modulating an important biological process and to then address variability in the biologic process by examining the effects of common variants in such “candidate” genes; 2. genome-wide association (GWA) unbiased approach to identify common genetic variants modulating disease susceptibility, physiologic traits, and variable drug responses;
3. An intermediate experimental approach, between single candidate gene variant and GWA approaches, is to consider the possibility that variability in a trait such as drug response is attributable to combinations of variants in functionally-linked sets of genes. This approach may be especially appealing to dissect the contributions of variable physiologic perturbations caused by disease to variable drug responses;
4. Combined approach focused on association of the information on genetic variation (including ncRNA) with other high dimensional data, such as gene expression profiling in cell lines or specific tissues, to identify networks of genes modulating variable drug response phenotypes.
This Research Topic aims to evaluate all different types of approaches to identifying genetic contributions to cardiovascular and neurovascular drug actions. The goal of this Research Topic is to underline the progress made in the past decade in the vascular pharmacogenomics /genetics field.
Another objective of this Research Topic is to pay particular attention to new discoveries relating the use of innovative genetic testing tests and technologies to inform, help and provide direction and guidance for clinicians to help managing vascular diseases.
This collection welcomes all types of manuscripts, including original studies, literature reviews and brief and/or extended reports. All material must cover vascular pharmacogenomics/genetics studied and documented by clinical and/or test evaluations.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Patients vary in their responses to drug therapy, and some of that variability is genetically determined. Vascular pharmacogenomics is the research approach aimed at identification of genomic markers that are associated with variability in drug response, drug-related outcomes, or drug-related adverse events. Examples from vascular specific therapeutic areas include cholesterol management, arrhythmias, stroke, heart failure, hypertension, warfarin anticoagulation, and anti-platelet agents.
The approaches to identifying genetic contributors to variable cardiovascular and neurovascular drug actions include:
1. Identification a series of genes modulating an important biological process and to then address variability in the biologic process by examining the effects of common variants in such “candidate” genes; 2. genome-wide association (GWA) unbiased approach to identify common genetic variants modulating disease susceptibility, physiologic traits, and variable drug responses;
3. An intermediate experimental approach, between single candidate gene variant and GWA approaches, is to consider the possibility that variability in a trait such as drug response is attributable to combinations of variants in functionally-linked sets of genes. This approach may be especially appealing to dissect the contributions of variable physiologic perturbations caused by disease to variable drug responses;
4. Combined approach focused on association of the information on genetic variation (including ncRNA) with other high dimensional data, such as gene expression profiling in cell lines or specific tissues, to identify networks of genes modulating variable drug response phenotypes.
This Research Topic aims to evaluate all different types of approaches to identifying genetic contributions to cardiovascular and neurovascular drug actions. The goal of this Research Topic is to underline the progress made in the past decade in the vascular pharmacogenomics /genetics field.
Another objective of this Research Topic is to pay particular attention to new discoveries relating the use of innovative genetic testing tests and technologies to inform, help and provide direction and guidance for clinicians to help managing vascular diseases.
This collection welcomes all types of manuscripts, including original studies, literature reviews and brief and/or extended reports. All material must cover vascular pharmacogenomics/genetics studied and documented by clinical and/or test evaluations.
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
